Propanc Biopharma, Inc.
1.3100-0.11 (-7.75%)
Oct 29, 4:00:00 PM EDT · NasdaqCM · PPCB · USD
Key Stats
Market Cap
16.78MP/E (TTM)
-Basic EPS (TTM)
-14.85Dividend Yield
0%Recent Filings
8-K
Preferred stock private placement
Propanc Biopharma entered a securities purchase agreement with Hexstone Capital on October 7, 2025, issuing 100 shares of newly created Series C Preferred Stock convertible into common stock at the lesser of $5.00 or 85% of recent low trading prices, alongside a warrant for up to 9,900 more Series C shares at $10,000 each. This private placement, pending Delaware filing, secures funding but risks substantial dilution for existing shareholders amid volatile markets. Yet, it bolsters liquidity. Deal closes soon.
10-K
FY2025 results
Propanc Biopharma posted a $58.9M net loss for FY2025 ended June 30, 2025, ballooning from $1.8M the prior year, driven by $51.3M in stock-based compensation from issuing millions of shares to executives and consultants at inflated prices around $6 each. No revenue yet as a clinical-stage biotech, but Q4 saw aggressive equity raises via convertible notes totaling $252K principal, many in default by year-end yet converted post-period, injecting cash for R&D momentum toward a planned Phase Ib trial in H2 2026. Debt burden eased sequentially in Q4 with $55K conversions, but derivative liabilities jumped to $404K from fair value swings. Liquidity strained at $0 cash, reliant on related-party loans; no dividends or buybacks. Outlook eyes CTA filing in H1 2026, but funding gaps loom large. Cancer stem cell therapies remain unproven, risking trial delays.
8-K
Propanc closes $4M offering, uplists
Propanc Biopharma closed a $4 million public offering of 1,000,000 common shares at $4.00 each on August 18, 2025, netting $3.34 million after expenses for working capital. The stock uplisted to Nasdaq under PPCB, starting trading August 15, while appointing independent directors Joseph Himy and Annie VanBroekhoven to key committees. Fresh capital bolsters biotech development. Forward-looking statements carry market risks.
8-K
CFO appointment announced
Propanc Biopharma appointed Jeannine Zimmerman as Chief Financial Officer effective August 13, 2025, following the July 31 board decision. The 48-year-old accounting graduate brings expertise in SEC filings, audits, SOX compliance, and diverse sectors from her roles at public firms. This leadership shift bolsters financial oversight for the biopharma developer. No compensation details disclosed.
8-K
Convertible note issuance closed
Propanc Biopharma closed a securities purchase agreement on July 25, 2025, issuing a convertible promissory note with $112,350 principal to 1800 Diagonal Lending for $107,000, earmarked for working capital. The note matures April 30, 2026, at 22% interest, convertible after 180 days at a 25% discount to recent trading prices, capped by a 4.99% ownership limit. Prepayment options fade after six months. High costs signal funding pressures.
CNBX
CNBX Pharmaceuticals Inc.
0.00+0.00
NBTX
Nanobiotix S.A.
17.99+0.36
NCNA
NuCana plc
3.95-0.24
PMCB
PharmaCyte Biotech, Inc.
0.96-0.02
PMVP
PMV Pharmaceuticals, Inc.
1.42-0.05
PROK
ProKidney Corp.
3.10+0.06
PRPO
Precipio, Inc.
20.66-0.34
PTIX
Protagenic Therapeutics, Inc.
2.58-0.18
PVCT
Provectus Biopharmaceuticals, I
0.07+0.00
TARA
Protara Therapeutics, Inc.
5.20+0.11